疏肝解郁胶囊治疗脑卒中后抑郁患者疗效及日常生活活动能力研究

Effect observation and the ability of daily life of Shuganjieyu capsule in the treatment of post-stroke depression

目的探讨疏肝解郁胶囊治疗脑卒中后抑郁的疗效、日常生活能力、安全性的研究。方法未服用过抗抑郁药物的脑卒中后抑郁患者40例做为对照组,实验组为40例服用疏肝解郁胶囊治疗前、治疗6 w末及12 w末脑卒中后抑郁的患者,采用汉密尔顿抑郁量表(HAMD)评分,日常生活活动能力量表(Barthel指数)评分。结果实验组未治疗前与对照组HAMD评分及Barthel指数评分比较无明显统计学差异(P>0.05),服用疏肝解郁胶囊治疗6 w末与对照组HAMD评分及Barthel指数评分有统计学差异(P<0.05),并且治疗12 w末与对照组HAMD评分及Barthel指数评分有明显的统计学差异(P<0.01)。同时HAMD评分有效率结果表明,对照组未服用疏肝解郁胶囊6 w及12 w末有效率为0%,治疗组服用疏肝解郁胶囊6 w及12 w末有效率分别为75%及85%。结论疏肝解郁胶囊能有效治疗脑卒后抑郁,并且能改善脑卒中后抑郁患者日常生活活动能力,不良反应较少,安全性高。

Objective To explore clinical efficacy,the ability of daily life and safety of Shuganjieyu capsule in the treatment of post-stroke depression. Methods The total of 40 patients with post-stroke depression who had never taken an- tidepressants as control group. The total of 40 patients with post - stroke depression take the Shuganjieyu capsule after 6 weeks and 12 weeks as study group. All patients were assessed with Hamilton Depression Scale（HAMD） and Barthel. Re- suits The control group of Scale （HAMD） and Barthel were no statistical difference compared to study group had never taken antidepressants（P 〉 0.05 ）. The study group of Scale（HAMD） and Barthel taken antidepressants after 6 weeks were statistical difference compared to control group（ P 〈 0.05 ）. And the study group of Scale（HAMD） and Barthel taken anti- depressants after 12 weeks were significant statisticaly different compared to control group（ P 〈 0.01 ）. The control group of Scale （HAMD）results show that effective were 0% after 6 weeks and 12 weeks have never taken Shuganjieyu capsule. The study group of Scale（ HAMD）results show that effective were 75% after 6 weeks and 85% after 12 weeks had taken Shu- ganjieyu capsule. Conclusion Shuganjieyu Capsule therapy for post-stroke depression is effective and safe treatment, and also improve the ability of daily life.